PMID- 32135429
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20231103
IS  - 1879-0046 (Electronic)
IS  - 0376-8716 (Print)
IS  - 0376-8716 (Linking)
VI  - 209
DP  - 2020 Apr 1
TI  - Parallel modeling of pain and depression in prediction of relapse during 
      buprenorphine and naloxone treatment: A finite mixture model.
PG  - 107940
LID - S0376-8716(20)30105-8 [pii]
LID - 10.1016/j.drugalcdep.2020.107940 [doi]
AB  - BACKGROUND: Relapse is common in treatment for opioid use disorders (OUDs). Pain 
      and depression often co-occur during OUD treatment, yet little is known about how 
      they influence relapse among patients with a primary diagnosis of prescription 
      opioid use disorder (POUD). Advanced statistical analyses that can simultaneously 
      model these two conditions may lead to targeted clinical interventions. METHOD: 
      The objective of this study was to utilize a discrete survival analysis with a 
      growth mixture model to test time to prescription opioid relapse, predicted by 
      parallel growth trajectories of depression and pain, in a clinical sample of 
      patients in buprenorphine/naloxone treatment. The latent class analysis 
      characterized heterogeneity with data collected from the National Institute of 
      Drug Abuse Clinical Trials Network project (CTN-0030). RESULTS: Results suggested 
      that a 4-class solution was the most parsimonious based on global fit indices and 
      clinical relevance. The 4 classes identified were: 1) low relapse, 2) high 
      depression and moderate pain, 3) high pain, and 4) high relapse. Odds ratios for 
      time-to-first use indicated no statistically significant difference in time to 
      relapse between the high pain and the high depression classes, but all other 
      classes differed significantly. CONCLUSION: This is the first longitudinal study 
      to characterize the influence of pain, depression, and relapse in patients 
      receiving buprenorphine and naloxone treatment. These results emphasize the need 
      to monitor the influence of pain and depression during stabilization on 
      buprenorphine and naloxone. Future work may identify appropriate interventions 
      that can be introduced to extend time-to-first prescription opioid use among 
      patients.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Vest, Noel A
AU  - Vest NA
AD  - Washington State University, Department of Psychology, Pullman, WA 99164-4820, 
      United States. Electronic address: noelvest@stanford.edu.
FAU - McPherson, Sterling
AU  - McPherson S
AD  - Washington State University, Elson S. Floyd College of Medicine, Analytics & 
      Psychopharmacology Laboratory (APPL), 412 E. Spokane Falls Blvd. Spokane, WA 
      99202-2131, United States. Electronic address: sterling.mcpherson@wsu.edu.
FAU - Burns, G Leonard
AU  - Burns GL
AD  - Washington State University, Department of Psychology, Pullman, WA 99164-4820, 
      United States. Electronic address: glburns@wsu.edu.
FAU - Tragesser, Sarah
AU  - Tragesser S
AD  - Washington State University, Department of Psychology, Pullman, WA 99164-4820, 
      United States. Electronic address: sarah_tragesser@wsu.edu.
LA  - eng
GR  - T32 DA035165/DA/NIDA NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200226
PL  - Ireland
TA  - Drug Alcohol Depend
JT  - Drug and alcohol dependence
JID - 7513587
RN  - 0 (Buprenorphine, Naloxone Drug Combination)
RN  - 0 (Narcotic Antagonists)
SB  - IM
MH  - Adult
MH  - Buprenorphine, Naloxone Drug Combination/*therapeutic use
MH  - Depression/diagnosis/*drug therapy/epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Latent Class Analysis
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Narcotic Antagonists/*therapeutic use
MH  - Opioid-Related Disorders/diagnosis/*drug therapy/epidemiology
MH  - Pain/diagnosis/*drug therapy/epidemiology
MH  - Predictive Value of Tests
MH  - Recurrence
PMC - PMC7173998
MID - NIHMS1570319
OTO - NOTNLM
OT  - Buprenorphine and naloxone treatment
OT  - Depression
OT  - Growth mixture modeling
OT  - Opioid substitution treatment
OT  - Pain
OT  - Prescription opioid use disorder
OT  - Survival
COIS- Declaration of Competing Interest The authors report no conflicts of interest.
EDAT- 2020/03/07 06:00
MHDA- 2021/01/13 06:00
PMCR- 2021/04/01
CRDT- 2020/03/06 06:00
PHST- 2019/10/25 00:00 [received]
PHST- 2020/02/17 00:00 [revised]
PHST- 2020/02/23 00:00 [accepted]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
PHST- 2020/03/06 06:00 [entrez]
PHST- 2021/04/01 00:00 [pmc-release]
AID - S0376-8716(20)30105-8 [pii]
AID - 10.1016/j.drugalcdep.2020.107940 [doi]
PST - ppublish
SO  - Drug Alcohol Depend. 2020 Apr 1;209:107940. doi: 
      10.1016/j.drugalcdep.2020.107940. Epub 2020 Feb 26.